The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...